Valiant Laboratories Ltd
Incorporated in 1980, Valiant Laboratories Limited is a pharmaceutical ingredient manufacturing company in India having focuses on manufacturing Paracetamol.[1]
- Market Cap ₹ 685 Cr.
- Current Price ₹ 158
- High / Low ₹ 227 / 139
- Stock P/E 23.6
- Book Value ₹ 24.3
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 6.49 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | |
|---|---|
| 334 | |
| 299 | |
| Operating Profit | 35 |
| OPM % | 11% |
| 5 | |
| Interest | 0 |
| Depreciation | 2 |
| Profit before tax | 38 |
| Tax % | 24% |
| 29 | |
| EPS in Rs | 8.91 |
| Dividend Payout % | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Sep 2023 | |
|---|---|---|
| Equity Capital | 33 | 33 |
| Reserves | 68 | 73 |
| 60 | 61 | |
| 52 | 49 | |
| Total Liabilities | 213 | 215 |
| 48 | 50 | |
| CWIP | 1 | 11 |
| Investments | 34 | 20 |
| 130 | 135 | |
| Total Assets | 213 | 215 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | |
|---|---|
| 56 | |
| -55 | |
| -1 | |
| Net Cash Flow | -0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | |
|---|---|
| Debtor Days | 97 |
| Inventory Days | 17 |
| Days Payable | 62 |
| Cash Conversion Cycle | 52 |
| Working Capital Days | 71 |
| ROCE % |
Documents
Announcements
- Certificate From PCS Under Regulation 40(9) 11 Apr
-
Compliance Certificate For The Period Ended March 31, 2024
11 Apr - Copy of Compliance Certificate under Regulation 7(3) of SEBI (LODR) duly signed on behalf of the company and by the RTA.
- Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot 10 Apr
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 10 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Apr - Certificate under Regulation 74(5) of SEBI (Depositories & Participants) Regulations 2018 for the Quarter ended March 31, 2024, received from M/s. Link Intime India Private …
Annual reports
No data available.
Business Profile[1] The company manufactures a single product, i.e., Paracetamol, which has several applications, like in treatment headache, muscle ache, arthritis, back ache, toothache, cold, and fever. Paracetamol is one of the most commonly taken analgesics worldwide and is recommended as the first-line therapy in pain conditions by the World Health Organization (WHO).